Lars-Olof Wahlund

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7136083/publications.pdf

Version: 2024-02-01

		87401		116156
125	5,153	40		66
papers	citations	h-index		g-index
			. '	
139	139	139		8771
all docs	docs citations	times ranked		citing authors

#	Article	IF	CITATIONS
1	Parsing heterogeneity within dementia with Lewy bodies using clustering of biological, clinical, and demographic data. Alzheimer's Research and Therapy, 2022, 14, 14.	3.0	10
2	The protective gene dose effect of the $\langle i \rangle APOE \langle i \rangle \langle i \rangle \hat{l} \mu 2 \langle i \rangle$ allele on gray matter volume in cognitively unimpaired individuals. Alzheimer's and Dementia, 2022, 18, 1383-1395.	0.4	13
3	Cognitive dedifferentiation as a function of cognitive impairment in the ADNI and MemClin cohorts. Aging, 2021, 13, 13430-13442.	1.4	2
4	Potential Virus Involvement in Alzheimer's Disease: Results from a Phase IIa Trial Evaluating Apovir, an Antiviral Drug Combination. Journal of Alzheimer's Disease Reports, 2021, 5, 1-19.	1.2	6
5	Effects of amyloid pathology and the APOE $\hat{l}\mu 4$ allele on the association between cerebrospinal fluid A $\hat{l}^2 38$ and A $\hat{l}^2 40$ and brain morphology in cognitively normal 70-years-olds. Neurobiology of Aging, 2021, 101, 1-12.	1.5	7
6	The Use of Magnetic Resonance Imaging Techniques in Assessing the Effects of Alcohol Consumption and Heavy Drinking on the Adolescent Brain: A Scoping Review Protocol. Brain Sciences, 2021, 11, 764.	1.1	0
7	Effects of Peroral Omega-3 Fatty Acid Supplementation on Cerebrospinal Fluid Biomarkers in Patients with Alzheimer's Disease: A Randomized Controlled Trialâ€"The OmegAD Study. Journal of Alzheimer's Disease, 2021, 83, 1291-1301.	1.2	10
8	Atrial Fibrillation, Stroke, and Silent Cerebrovascular Disease. Neurology, 2021, 97, e1608-e1619.	1.5	24
9	Deep learning from MRI-derived labels enables automatic brain tissue classification on human brain CT. Neurolmage, 2021, 244, 118606.	2.1	13
10	Demographic and Clinical Characteristics of Individuals with Mild Cognitive Impairment Related to Grade of Alcohol Consumption. Dementia and Geriatric Cognitive Disorders, 2021, 50, 491-497.	0.7	0
11	Cerebrospinal Fluid Biomarkers, Brain Structural and Cognitive Performances Between Normotensive and Hypertensive Controlled, Uncontrolled and Untreated 70-Year-Old Adults. Frontiers in Aging Neuroscience, 2021, 13, 777475.	1.7	4
12	The association of Alzheimer's disease and cerebrovascular disease biomarkers towards the neurodegeneration of the cholinergic pathways. Alzheimer's and Dementia, 2021, 17, .	0.4	0
13	Association of deepâ€learning–derived brain computed tomography measures with cognition and bloodâ€based biomarkers of neurodegenerative diseases. Alzheimer's and Dementia, 2021, 17, .	0.4	O
14	Global Burden of Small Vessel Disease–Related Brain Changes on MRI Predicts Cognitive and Functional Decline. Stroke, 2020, 51, 170-178.	1.0	115
15	Functional Connectivity Alterations of the Temporal Lobe and Hippocampus in Semantic Dementia and Alzheimer's Disease. Journal of Alzheimer's Disease, 2020, 76, 1461-1475.	1.2	24
16	Structural brain imaging as a diagnostic tool in dementia, why and how?. Psychiatry Research - Neuroimaging, 2020, 306, 111183.	0.9	9
17	An epigenome-wide association study of Alzheimer's disease blood highlights robust DNA hypermethylation in the HOXB6 gene. Neurobiology of Aging, 2020, 95, 26-45.	1.5	51
18	Cerebrospinal Fluid Metals and the Association with Cerebral Small Vessel Disease. Journal of Alzheimer's Disease, 2020, 78, 1229-1236.	1.2	9

#	Article	IF	CITATIONS
19	Editorial. Psychiatry Research - Neuroimaging, 2020, 306, 111175.	0.9	O
20	Sex differences in CSF biomarkers for neurodegeneration and bloodâ€brain barrier integrity. Alzheimer's and Dementia, 2020, 16, e038588.	0.4	0
21	Atrial fibrillation and the interaction with stroke in relation to white matter lesion volumes: A populationâ€based study in 70â€yearâ€olds. Alzheimer's and Dementia, 2020, 16, e043296.	0.4	0
22	The cholinergic system in subtypes of Alzheimer's disease: an in vivo longitudinal MRI study. Alzheimer's Research and Therapy, 2020, 12, 51.	3.0	41
23	The MemClin project: a prospective multi memory clinics study targeting early stages of cognitive impairment. BMC Geriatrics, 2020, 20, 93.	1.1	6
24	The Power of EEG to Predict Conversion from Mild Cognitive Impairment and Subjective Cognitive Decline to Dementia. Dementia and Geriatric Cognitive Disorders, 2020, 49, 38-47.	0.7	25
25	Changes in the left temporal microstate are a sign of cognitive decline in patients with Alzheimer's disease. Brain and Behavior, 2020, 10, e01630.	1.0	22
26	Evaluating severity of white matter lesions from computed tomography images with convolutional neural network. Neuroradiology, 2020, 62, 1257-1263.	1.1	8
27	Cholinergic dysfunction, neurodegeneration, and amyloid-beta pathology in neurodegenerative diseases. Psychiatry Research - Neuroimaging, 2020, 302, 111099.	0.9	9
28	Predicting Fazekas scores from automatic segmentations of white matter signal abnormalities. Aging, 2020, 12, 894-901.	1.4	32
29	Brain Atrophy Subtypes and the ATN Classification Scheme in Alzheimer's Disease. Neurodegenerative Diseases, 2020, 20, 153-164.	0.8	6
30	Oscillatory connectivity as a diagnostic marker of dementia due to Alzheimer's disease. Clinical Neurophysiology, 2019, 130, 1889-1899.	0.7	30
31	<i>APOE</i> and cortical superficial siderosis in CAA. Neurology, 2019, 93, e358-e371.	1.5	42
32	AVRA: Automatic visual ratings of atrophy from MRI images using recurrent convolutional neural networks. NeuroImage: Clinical, 2019, 23, 101872.	1.4	20
33	Inflammatory biomarkers in Alzheimer's disease plasma. Alzheimer's and Dementia, 2019, 15, 776-787.	0.4	134
34	A signature pattern of cortical atrophy in dementia with Lewy bodies: A study on 333 patients from the European DLB consortium. Alzheimer's and Dementia, 2019, 15, 400-409.	0.4	60
35	Brain myoinositol as a potential marker of amyloid-related pathology. Neurology, 2019, 92, e395-e405.	1.5	30
36	Androgen deprivation therapy for prostate cancer and risk of dementia. BJU International, 2019, 124, 87-92.	1.3	26

3

#	Article	IF	CITATIONS
37	Heterogeneous patterns of brain atrophy in Alzheimer's disease. Neurobiology of Aging, 2018, 65, 98-108.	1.5	110
38	Default Mode Network Complexity and Cognitive Decline in Mild Alzheimer's Disease. Frontiers in Neuroscience, 2018, 12, 770.	1.4	103
39	The contribution of small vessel disease to subtypes of Alzheimer's disease: a study on cerebrospinal fluid and imaging biomarkers. Neurobiology of Aging, 2018, 70, 18-29.	1.5	48
40	EEG Theta Power Is an Early Marker of Cognitive Decline in Dementia due to Alzheimer's Disease. Journal of Alzheimer's Disease, 2018, 64, 1359-1371.	1.2	100
41	Differential Associations of IL-4 With Hippocampal Subfields in Mild Cognitive Impairment and Alzheimer's Disease. Frontiers in Aging Neuroscience, 2018, 10, 439.	1.7	21
42	The heterogeneity within Alzheimer's disease. Aging, 2018, 10, 3058-3060.	1.4	41
43	Perivascular Spaces in Old Age: Assessment, Distribution, and Correlation with White Matter Hyperintensities. American Journal of Neuroradiology, 2018, 39, 70-76.	1.2	45
44	Cerebral microbleeds topography and cerebrospinal fluid biomarkers in cognitive impairment. Journal of Cerebral Blood Flow and Metabolism, 2017, 37, 1006-1013.	2.4	24
45	Predicting Cognitive Decline across Four Decades in Mutation Carriers and Non-carriers in Autosomal-Dominant Alzheimer's Disease. Journal of the International Neuropsychological Society, 2017, 23, 195-203.	1.2	18
46	27-Hydroxycholesterol impairs neuronal glucose uptake through an IRAP/GLUT4 system dysregulation. Journal of Experimental Medicine, 2017, 214, 699-717.	4.2	64
47	The interactive effect of demographic and clinical factors on hippocampal volume: A multicohort study on 1958 cognitively normal individuals. Hippocampus, 2017, 27, 653-667.	0.9	20
48	Distinct subtypes of Alzheimer's disease based on patterns of brain atrophy: longitudinal trajectories and clinical applications. Scientific Reports, 2017, 7, 46263.	1.6	141
49	Specific patterns of whole-brain structural covariance of the anterior and posterior hippocampus in young APOE $\hat{l}\mu 4$ carriers. Behavioural Brain Research, 2017, 326, 256-264.	1.2	12
50	The Effects of Gene Mutations onÂDefaultÂMode Network inÂFamilialÂAlzheimer's Disease. Journal of Alzheimer's Disease, 2017, 56, 327-334.	1.2	8
51	Imaging biomarkers of dementia: recommended visual rating scales with teaching cases. Insights Into Imaging, 2017, 8, 79-90.	1.6	67
52	Relation of Odor Identification with Alzheimer's Disease Markers in Cerebrospinal Fluid and Cognition. Journal of Alzheimer's Disease, 2017, 60, 1025-1034.	1.2	33
53	Memory Correlates of Alzheimer's Disease Cerebrospinal Fluid Markers: A Longitudinal Cohort Study. Journal of Alzheimer's Disease, 2017, 60, 1119-1128.	1.2	27
54	DHA-rich n–3 fatty acid supplementation decreases DNA methylation in blood leukocytes: the OmegAD study. American Journal of Clinical Nutrition, 2017, 106, 1157-1165.	2.2	46

#	Article	IF	CITATIONS
55	Monitoring disease progression in mild cognitive impairment: Associations between atrophy patterns, cognition, APOE and amyloid. NeuroImage: Clinical, 2017, 16, 418-428.	1.4	23
56	MRI of the Swallow Tail Sign: A Useful Marker in the Diagnosis of Lewy Body Dementia?. American Journal of Neuroradiology, 2017, 38, 1737-1741.	1.2	50
57	Mixed brain lesions mediate the association between cardiovascular risk burden and cognitive decline in old age: A populationâ€based study. Alzheimer's and Dementia, 2017, 13, 247-256.	0.4	42
58	Does Fatty Acid Composition in Subcutaneous Adipose Tissue Differ between Patients with Alzheimer's Disease and Cohabiting Proxies?. Journal of Alzheimer's Disease, 2017, 61, 515-519.	1.2	2
59	[ICâ€Pâ€123]: ATROPHY OF THE POSTERIOR SUBICULUM IS ASSOCIATED WITH MEMORY IMPAIRMENT, TAU AND PATHOLOGY IN NONâ€DEMENTED INDIVIDUALS. Alzheimer's and Dementia, 2017, 13, P94.	O AÎ ² O.4	O
60	[P2–194]: USING EMERGING CEREBROSPINAL FLUID MARKERS TO CHARACTERIZE SUSPECTED NONâ€ALZHEIMER'S DISEASE PATHOPHYSIOLOGY (SNAP) IN INDIVIDUALS WITH MILD COGNITIVE IMPAIRMENT. Alzheimer's and Dementia, 2017, 13, P680.	0.4	0
61	Physical activity level in people with age related white matter changes correlates to better motor performance, lower comorbidity and higher cognitive level. BMC Geriatrics, 2017, 17, 142.	1.1	5
62	Diverging Progression of Network Disruption and Atrophy in Alzheimer's Disease and Semantic Dementia. Journal of Alzheimer's Disease, 2016, 55, 981-993.	1.2	9
63	Cerebrospinal Fluid Biomarkers for the Differential Diagnosis between Alzheimer's Disease and Frontotemporal Lobar Degeneration: Systematic Review, HSROC Analysis, and Confounding Factors. Journal of Alzheimer's Disease, 2016, 55, 625-644.	1.2	44
64	P2â€270: Longitudinal Investigation of an MRIâ€Based Alzheimer's Disease Diagnostic Index in Adni. Alzheimer's and Dementia, 2016, 12, P732.	0.4	1
65	The Effect of Age Correction on Multivariate Classification in Alzheimer's Disease, with a Focus on the Characteristics of Incorrectly and Correctly Classified Subjects. Brain Topography, 2016, 29, 296-307.	0.8	44
66	Myo-inositol changes precede amyloid pathology and relate to <i>APOE</i> genotype in Alzheimer disease. Neurology, 2016, 86, 1754-1761.	1.5	66
67	Cortical superficial siderosis. Neurology, 2016, 87, 1110-1117.	1.5	37
68	Disrupted Network Topology in Patients with Stable and Progressive Mild Cognitive Impairment and Alzheimer's Disease. Cerebral Cortex, 2016, 26, 3476-3493.	1.6	110
69	The APOE4 allele shows opposite sex bias in microbleeds and Alzheimer's disease of humans and mice. Neurobiology of Aging, 2016, 37, 47-57.	1.5	70
70	Quantitative validation of a visual rating scale for frontal atrophy: associations with clinical status, APOE e4, CSF biomarkers and cognition. European Radiology, 2016, 26, 2597-2610.	2.3	39
71	Cerebral microbleeds as a biomarker in Alzheimer's disease? A review in the field. Biomarkers in Medicine, 2016, 10, 9-18.	0.6	26
72	Discovering EEG resting state alterations of semantic dementia. Clinical Neurophysiology, 2016, 127, 2175-2181.	0.7	38

#	Article	IF	Citations
7 3	Cerebrospinal fluid profiles with increasing number of cerebral microbleeds in a continuum of cognitive impairment. Journal of Cerebral Blood Flow and Metabolism, 2016, 36, 621-628.	2.4	40
74	Apolipoprotein E $\ddot{l}\mu4$ is positively related to spatial performance but unrelated to hippocampal volume in healthy young adults. Behavioural Brain Research, 2016, 299, 11-18.	1.2	14
7 5	P1-020: Structural brain changes mediate the association between cardiovascular risk burden and cognitive decline in old age: A population-based study. , 2015, 11, P344-P344.		0
76	O1-04-05: Hypertension, APOE-É>4 allele, regional white-matter hyperintensities, and cognitive decline in old age: A population-based study. , 2015, 11, P134-P134.		0
77	O1-03-03: Olfactory dysfunction may predict Alzheimer's disease related tau pathology in cerebrospinal fluid (CSF)., 2015, 11, P130-P130.		0
78	O4-03-01: Early detection of Alzheimer's disease (AD)-related amyloid and tau pathology: A computerized versus a paper-and-pencil memory test., 2015, 11, P272-P272.		0
79	Plasma Fatty Acid Profiles in Relation toÂCognition and Gender in Alzheimer's Disease Patients During Oral Omega-3 FattyÂAcid Supplementation: The OmegADÂStudy. Journal of Alzheimer's Disease, 2015, 48, 805-812.	1.2	82
80	Medial Temporal Lobe Atrophy and Depressive Symptoms in Elderly Patients With and Without Alzheimer Disease. Journal of Geriatric Psychiatry and Neurology, 2015, 28, 40-48.	1,2	22
81	Changes in CSF cholinergic biomarkers in response to cell therapy with NGF in patients with Alzheimer's disease. Alzheimer's and Dementia, 2015, 11, 1316-1328.	0.4	50
82	Automated CT-based segmentation and quantification of total intracranial volume. European Radiology, 2015, 25, 3151-3160.	2.3	17
83	Aberrant cerebral network topology and mild cognitive impairment in early Parkinson's disease. Human Brain Mapping, 2015, 36, 2980-2995.	1.9	87
84	Shape Abnormalities of the Caudate Nucleus Correlate with Poorer Gait and Balance: Results from a Subset of the LADIS Study. American Journal of Geriatric Psychiatry, 2015, 23, 59-71.e1.	0.6	16
85	Physical activity in the elderly is associated with improved executive function and processing speed: the LADIS Study. International Journal of Geriatric Psychiatry, 2015, 30, 744-750.	1.3	51
86	Head-to-Head Comparison of Two Popular Cortical Thickness Extraction Algorithms: A Cross-Sectional and Longitudinal Study. PLoS ONE, 2015, 10, e0117692.	1.1	53
87	Meta-Review of CSF Core Biomarkers in Alzheimerââ,¬â,,¢s Disease: The State-of-the-Art after the New Revised Diagnostic Criteria. Frontiers in Aging Neuroscience, 2014, 6, 47.	1.7	105
88	Application of a MRI based index to longitudinal atrophy change in Alzheimer disease, mild cognitive impairment and healthy older individuals in the AddNeuroMed cohort. Frontiers in Aging Neuroscience, 2014, 6, 145.	1.7	29
89	The effects of intracranial volume adjustment approaches on multiple regional MRI volumes in healthy aging and Alzheimer's disease. Frontiers in Aging Neuroscience, 2014, 6, 264.	1.7	322
90	IC-P-120: PREVALENCE, TOPOGRAPHY, AND RISK FACTORS OF CEREBRAL MICROBLEEDS IN DEMENTIA. , 2014, 10, P67-P68.		0

#	Article	IF	CITATIONS
91	Cerebral inflammation is an underlying mechanism of early death in Alzheimer's disease: a 13-year cause-specific multivariate mortality study. Alzheimer's Research and Therapy, 2014, 6, 41.	3.0	33
92	The Australian, US, Scandinavian Imaging Exchange (AUSSIE): an innovative, virtually-integrated health research network embedded in health care. Australasian Psychiatry, 2014, 22, 260-265.	0.4	4
93	Galantamine Versus Risperidone Treatment of Neuropsychiatric Symptoms in Patients with Probable Dementia: An Open Randomized Trial. American Journal of Geriatric Psychiatry, 2014, 22, 341-348.	0.6	26
94	Shape Analysis of the Corpus Callosum in Alzheimer's Disease and Frontotemporal Lobar Degeneration Subtypes. Journal of Alzheimer's Disease, 2014, 40, 897-906.	1.2	17
95	Vitamin D in Relation to Cognitive Impairment, Cerebrospinal Fluid Biomarkers, and Brain Volumes. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2014, 69, 1132-1138.	1.7	68
96	Cognitive decline is mediated by gray matter changes during middle age. Neurobiology of Aging, 2014, 35, 1086-1094.	1.5	48
97	Response to Bogaiksy's Letter to the Editor. American Journal of Geriatric Psychiatry, 2014, 22, 951.	0.6	0
98	Sex differences in volume and structural covariance of the anterior and posterior hippocampus. NeuroImage, 2014, 99, 215-225.	2.1	68
99	Brain Changes in Alzheimer's Disease Patients with Implanted Encapsulated Cells Releasing Nerve Growth Factor. Journal of Alzheimer's Disease, 2014, 43, 1059-1072.	1.2	71
100	Improving CSF Biomarkersââ,¬â,,¢ Performance for Predicting Progression from Mild Cognitive Impairment to Alzheimerââ,¬â,,¢s Disease by Considering Different Confounding Factors: A Meta-Analysis. Frontiers in Aging Neuroscience, 2014, 6, 287.	1.7	44
101	P3-180: DISTINCT NEURAL SIGNATURES OF DIFFERENT APOE GENE POLYMORPHISMS ON HIPPOCAMPAL VOLUME: A LARGE SCALE STUDY IN ALZHEIMER'S DISEASE AND NORMAL HEALTHY AGEING. , 2014, 10, P694-P694.		O
102	O5-02-01: PREVALENCE, TOPOGRAPHY, AND RISK FACTORS OF CEREBRAL MICROBLEEDS IN DEMENTIA. , 2014, 10, P290-P291.		0
103	IC-P-092: A LONGITUDINAL STUDY OF AN MRI BASED SEVERITY INDEX IN THE ADDNEUROMED COHORT. , 2014, 10, P52-P52.		0
104	The neural correlates of self-paced finger tapping in bipolar depression with motor retardation. Acta Neuropsychiatrica, 2013, 25, 43-51.	1.0	12
105	Overtime reliability of medial temporal lobe atrophy rating in a clinical setting. Acta Radiologica, 2012, 53, 318-323.	0.5	35
106	Comparison between visual assessment of MTA and hippocampal volumes in an elderly, non-demented population. Acta Radiologica, 2012, 53, 573-579.	0.5	32
107	AddNeuroMed and ADNI: Similar patterns of Alzheimer's atrophy and automated MRI classification accuracy in Europe and North America. NeuroImage, 2011, 58, 818-828.	2.1	121
108	Sensitivity and Specificity of Medial Temporal Lobe Visual Ratings and Multivariate Regional MRI Classification in Alzheimer's Disease. PLoS ONE, 2011, 6, e22506.	1.1	103

#	Article	IF	CITATIONS
109	The AddNeuroMed framework for multiâ€centre MRI assessment of Alzheimer's disease : experience from the first 24 months. International Journal of Geriatric Psychiatry, 2011, 26, 75-82.	1.3	127
110	APOE & amp; #949; 2 Allele Is Associated with Larger Regional Cortical Thicknesses and Volumes. Dementia and Geriatric Cognitive Disorders, 2010, 30, 229-237.	0.7	40
111	MRI Measures of Alzheimer's Disease and the AddNeuroMed Study. Annals of the New York Academy of Sciences, 2009, 1180, 47-55.	1.8	121
112	AddNeuroMedâ€"The European Collaboration for the Discovery of Novel Biomarkers for Alzheimer's Disease. Annals of the New York Academy of Sciences, 2009, 1180, 36-46.	1.8	193
113	Nâ€3 fatty acid treatment and plasma transthyretin in patients with Alzheimer's disease. FASEB Journal, 2009, 23, 543.10.	0.2	0
114	White matter changes and late-life depressive symptoms. British Journal of Psychiatry, 2007, 191, 212-217.	1.7	141
115	Evidence-based Evaluation of Magnetic Resonance Imaging as a Diagnostic Tool in Dementia Workup. Topics in Magnetic Resonance Imaging, 2005, 16 , $427-437$.	0.7	40
116	Mild cognitive impairment: experience from a memory clinic. Acta Neurologica Scandinavica, 2003, 107, 21-24.	1.0	69
117	Mild cognitive impairment: experience from a memory clinic. Acta Neurologica Scandinavica, Supplement, 2003, 179, 21-4.	0.7	10
118	Investigations of a CA repeat in the oestrogen receptor \hat{l}^2 gene in patients with Alzheimer's disease. European Journal of Human Genetics, 2001, 9, 802-804.	1.4	46
119	Evaluation of linear registration algorithms for brain SPECT and the errors due to hypoperfusion lesions. Medical Physics, 2001, 28, 1660-1668.	1.6	62
120	Cerebrospinal fluid A?42 is increased early in sporadic Alzheimer's disease and declines with disease progression. Annals of Neurology, 1999, 45, 504-511.	2.8	224
121	Decreased α-secretase-cleaved amyloid precursor protein as a diagnostic marker for Alzheimer's diseas. Nature Medicine, 1995, 1, 829-832.	15.2	163
122	Activation of monoamine oxidase by high molecular weight fractions of human plasma. Acta Physiologica Scandinavica, 1984, 120, 337-341.	2.3	6
123	Kinetic aspects of monoamine oxidase activity in twins with psychoses. Clinical Genetics, 1981, 19, 395-400.	1.0	7
124	Activity of platelet monoamine oxidase in apparently healthy subjects. Clinical Genetics, 1981, 19, 400-405.	1.0	3
125	Platelet monoamine oxidase activity in schlzophrenic familiesâ€kinetic aspects. Clinical Genetics, 1981, 19, 405-409.	1.0	3